Rentschler Biotechnologie GmbH, a contract development and manufacturing organization (CDMO) for biopharmaceuticals, has recently opened a new single-use bioreactor at the Companyâs site in Laupheim with a capacity of 2,000 liters. Rentschler continues to expand its cGMP manufacturing capacity only a few weeks after putting into operation an innovative Twin system with two 3,000 liter stainless steel bioreactors.
In combination with its first 2,000 liter single-use bioreactor put into operation in 2015, Rentschler now has two 1,000 liter and two 2,000 liter single-use manufacturing systems available. This enables the complete manufacturing of recombinant proteins in single-use bioreactors, also for late stage clinical development and market supply of biopharmaceuticals for the treatment of severe illnesses. âOnly a few weeks after putting into operation our Twin system, Rentschler again is expanding its manufacturing capacity with this new 2,000 liter single-use bioreactor. This capacity expansion will enable us to meet the continuous growth in international business,â? Dr. Frank Mathias, Chief Executive Officer of Rentschler Biotechnologie GmbH, commented.
Rentschler offers targeted and client-specific solutions that meet highly diverse requirements in terms of scale, manufacturing volumes, and manufacturing characteristics and therefore maximize the efficiency and suitability of biopharmaceutical manufacturing. âIn the future, providing both, single-use and stainless steel technologies, will continue to play an important role and enable greater flexibility â also for our clients. We align our goals with our clients’ objectives,â? Dr. Frank Mathias added.